+

WO2005113786A3 - Diagnostics and therapeutics for diseases associated with chymase (cma1) - Google Patents

Diagnostics and therapeutics for diseases associated with chymase (cma1) Download PDF

Info

Publication number
WO2005113786A3
WO2005113786A3 PCT/EP2005/004897 EP2005004897W WO2005113786A3 WO 2005113786 A3 WO2005113786 A3 WO 2005113786A3 EP 2005004897 W EP2005004897 W EP 2005004897W WO 2005113786 A3 WO2005113786 A3 WO 2005113786A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
cma1
chymase
therapeutics
diagnostics
Prior art date
Application number
PCT/EP2005/004897
Other languages
French (fr)
Other versions
WO2005113786A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts filed Critical Bayer Healthcare Ag
Priority to EP05740171A priority Critical patent/EP1766042A2/en
Publication of WO2005113786A2 publication Critical patent/WO2005113786A2/en
Publication of WO2005113786A3 publication Critical patent/WO2005113786A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21039—Chymase (3.4.21.39)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)

Abstract

The invention provides a human CMA1 which is associated with the cardiovascular diseases, infections, metabolic diseases, dermatological diseases, gastroenterological diseases, cancer, inflammation, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, infections, metabolic diseases, dermatological diseases, gastroenterological diseases, cancer, inflammation, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of CMA1 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2005/004897 2004-05-21 2005-05-06 Diagnostics and therapeutics for diseases associated with chymase (cma1) WO2005113786A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05740171A EP1766042A2 (en) 2004-05-21 2005-05-06 Diagnostics and therapeutics for diseases associated with chymase (cma1)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04012033.9 2004-05-21
EP04012033 2004-05-21

Publications (2)

Publication Number Publication Date
WO2005113786A2 WO2005113786A2 (en) 2005-12-01
WO2005113786A3 true WO2005113786A3 (en) 2006-02-09

Family

ID=34966986

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/004897 WO2005113786A2 (en) 2004-05-21 2005-05-06 Diagnostics and therapeutics for diseases associated with chymase (cma1)

Country Status (2)

Country Link
EP (1) EP1766042A2 (en)
WO (1) WO2005113786A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0618450A2 (en) * 2005-11-10 2011-08-30 Synergenz Bioscience Ltd method, as well as the use of at least one polymorphism, for the determination and assessment of the risk of a subject developing acute coronary syndrome, nucleotide probes and / or primers, nucleic acid and antibody microarray, method for screening compounds, and for evaluation of possible sensitivity of a subject, kit and use of an agent capable of modulating mmp12 activity
TWI532842B (en) 2009-06-11 2016-05-11 力博美科股份有限公司 Aptamer against chymase and use thereof
EP2524927A1 (en) * 2011-05-20 2012-11-21 Covagen AG New chymase binding compounds and medical uses thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567602A (en) * 1992-08-12 1996-10-22 Arris Pharmaceutical Corporation Recombinant production of chymase
JPH10245384A (en) * 1997-03-05 1998-09-14 Teijin Ltd New triazinesulfone derivative
JP2001031636A (en) * 1999-05-18 2001-02-06 Senju Pharmaceut Co Ltd alpha-KETOAMIDE DERIVATIVE AND ITS MEDICAL USE
WO2002068579A2 (en) * 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
JP2002300886A (en) * 2001-04-06 2002-10-15 Katakura Industries Co Ltd Stable recombinant human chymase, method for producing the same, and screening method using the same
US6607879B1 (en) * 1998-02-09 2003-08-19 Incyte Corporation Compositions for the detection of blood cell and immunological response gene expression
JP2003235556A (en) * 2002-02-15 2003-08-26 Katakura Industries Co Ltd Anti-human chymase monoclonal antibodies and their use
WO2004063340A2 (en) * 2003-01-13 2004-07-29 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cardiovascular disease using 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061,17662,1468,12282, 6350, 9035,1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123,12788,17729, 65552,1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32612, 10671, 261, 44570, 4

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567602A (en) * 1992-08-12 1996-10-22 Arris Pharmaceutical Corporation Recombinant production of chymase
JPH10245384A (en) * 1997-03-05 1998-09-14 Teijin Ltd New triazinesulfone derivative
US6607879B1 (en) * 1998-02-09 2003-08-19 Incyte Corporation Compositions for the detection of blood cell and immunological response gene expression
JP2001031636A (en) * 1999-05-18 2001-02-06 Senju Pharmaceut Co Ltd alpha-KETOAMIDE DERIVATIVE AND ITS MEDICAL USE
WO2002068579A2 (en) * 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
JP2002300886A (en) * 2001-04-06 2002-10-15 Katakura Industries Co Ltd Stable recombinant human chymase, method for producing the same, and screening method using the same
JP2003235556A (en) * 2002-02-15 2003-08-26 Katakura Industries Co Ltd Anti-human chymase monoclonal antibodies and their use
WO2004063340A2 (en) * 2003-01-13 2004-07-29 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cardiovascular disease using 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061,17662,1468,12282, 6350, 9035,1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123,12788,17729, 65552,1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32612, 10671, 261, 44570, 4

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CAUGHEY G H ET AL: "STRUCTURE CHROMOSOMAL ASSIGNMENT AND DEDUCED AMINO ACID SEQUENCE OF A HUMAN GENE FOR MAST CELL CHYMASE", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 266, no. 20, 1991, pages 12956 - 12963, XP002164694, ISSN: 0021-9258 *
JIN DENAN ET AL: "Chymase-derived angiotensin II and arrhythmias after myocardial infarction.", FOLIA PHARMACOLOGICA JAPONICA, vol. 124, no. 2, August 2004 (2004-08-01), pages 77 - 82, XP008050647, ISSN: 0015-5691 *
LIAO, Y. & HUSAIN, A.: "THE CHYMASE-ANGIOTENSIN SYSTEM IN HUMANS: BIOCHEMISTRY, THE CHYMASE-ANGIOTENSIN SYSTEM IN HUMANS: BIOCHEMISTRY, MOLECULAR BIOLOGY AND POTENTIAL ROLE IN CARDIOVASCULAR DISEASES", CANADIAN JOURNAL OF CARDIOLOGY, vol. 11, no. F, 1 August 1995 (1995-08-01), pages 13F - 19F, XP000565787 *
NISHIMURA HIKARU ET AL: "Angiotensin I converting enzyme and chymase in cardiovascular tissues", KIDNEY INTERNATIONAL SUPPLEMENT, vol. 0, no. 55, 1996, pages S18 - S23, XP008050706, ISSN: 0098-6577 *
NIWATA S ET AL: "substituted 3-(Phenylsulfonyl)-1-phenylimidazolidine-2,4-dione derivatives as novel nonpeptide inhibitors of human heart chymase", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 40, no. 14, 1997, pages 2156 - 2163, XP002122640, ISSN: 0022-2623 *

Also Published As

Publication number Publication date
WO2005113786A2 (en) 2005-12-01
EP1766042A2 (en) 2007-03-28

Similar Documents

Publication Publication Date Title
WO2006027147A3 (en) Diagnostics and therapeutics for diseases associated with adrenomedullin receptor (amdr)
WO2005093092A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 44 (gpr44)
WO2005106012A3 (en) Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1)
WO2006010517A3 (en) Diagnostics and therapeutics for diseases associated with fibroblast activation protein (fap)
WO2005100990A3 (en) Diagnostics and therapeutics for diseases associated with purinoceptor 2 type y (p2y2)
WO2005103684A3 (en) Diagnostics and therapeutics for diseases associated with cx3c chemokine receptor 1 (cx3cr1)
WO2005113786A3 (en) Diagnostics and therapeutics for diseases associated with chymase (cma1)
WO2006021343A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine receptor 3a (5-ht3a)
WO2005076007A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y12 (p2y12)
WO2006010514A3 (en) Diagnostics and therapeutics for diseases associated with dual specificity mitogen-activated protein kinase kinase 5 (map2k5)
WO2005093091A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26)
WO2006013015A3 (en) Diagnostics and therapeutics for diseases associated with marapsin (mpn)
WO2005106486A3 (en) Diagnostic and therapeutics for diseases associated with dipeptidyl-peptidase 3(dpp3)
WO2006013013A3 (en) Diagnostics and therapeutics for diseases associated with protective protein for beta-galactosidase (ppgb)
WO2005100997A3 (en) Diagnostics and therapeutics for diseases associated with tachykinin receptor 3 (tacr3)
WO2005073729A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y11 (p2y11)
WO2005085469A3 (en) Diagnostics and therapeutics for diseases associated with rho-associated protein kinase 1 (rock1)
WO2005026719A3 (en) Diagnostics and therapeutics for diseases associated with transporter slc22a3 (slc22a3)
WO2006005470A3 (en) Diagnostics and therapeutics for diseases associated with mas related g-protein coupled receptor e (mrge)
WO2006040047A3 (en) Diagnostics and therapeutics for diseases associated with rho/rac-interacting citron kinase (cit)
WO2006010497A3 (en) Diagnostics and therapeutics for diseases associated with choline kinase (chk)
WO2006013012A3 (en) Diagnostics and therapeutics for diseases associated with napsin 1 (nap1)
WO2006013014A3 (en) Diagnostics and therapeutics for diseases associated with prostate-specific membrane antigen-like protein (psmal)
WO2005114210A8 (en) Diagnostics and therapeutics for diseases associated with g protein-dependent receptor kinase 3 (grk3)
WO2005101011A3 (en) Diagnostics and therapeutics for diseases associated with lxr-alpha (lxra)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005740171

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005740171

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载